1. Home
  2. SUNS vs SCYX Comparison

SUNS vs SCYX Comparison

Compare SUNS & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SUNS
  • SCYX
  • Stock Information
  • Founded
  • SUNS 2023
  • SCYX 1999
  • Country
  • SUNS United States
  • SCYX United States
  • Employees
  • SUNS N/A
  • SCYX N/A
  • Industry
  • SUNS Real Estate Investment Trusts
  • SCYX Biotechnology: Pharmaceutical Preparations
  • Sector
  • SUNS Real Estate
  • SCYX Health Care
  • Exchange
  • SUNS Nasdaq
  • SCYX Nasdaq
  • Market Cap
  • SUNS 104.3M
  • SCYX 50.3M
  • IPO Year
  • SUNS N/A
  • SCYX 2014
  • Fundamental
  • Price
  • SUNS $13.56
  • SCYX $1.16
  • Analyst Decision
  • SUNS Buy
  • SCYX Buy
  • Analyst Count
  • SUNS 1
  • SCYX 1
  • Target Price
  • SUNS $17.50
  • SCYX N/A
  • AVG Volume (30 Days)
  • SUNS 68.1K
  • SCYX 344.9K
  • Earning Date
  • SUNS 02-15-2025
  • SCYX 11-06-2024
  • Dividend Yield
  • SUNS 4.50%
  • SCYX N/A
  • EPS Growth
  • SUNS N/A
  • SCYX N/A
  • EPS
  • SUNS 0.03
  • SCYX N/A
  • Revenue
  • SUNS $734,226.00
  • SCYX $8,566,000.00
  • Revenue This Year
  • SUNS N/A
  • SCYX N/A
  • Revenue Next Year
  • SUNS N/A
  • SCYX $365.06
  • P/E Ratio
  • SUNS $136.47
  • SCYX N/A
  • Revenue Growth
  • SUNS N/A
  • SCYX N/A
  • 52 Week Low
  • SUNS $8.11
  • SCYX $0.90
  • 52 Week High
  • SUNS $15.74
  • SCYX $3.07
  • Technical
  • Relative Strength Index (RSI)
  • SUNS N/A
  • SCYX 46.95
  • Support Level
  • SUNS N/A
  • SCYX $1.15
  • Resistance Level
  • SUNS N/A
  • SCYX $1.49
  • Average True Range (ATR)
  • SUNS 0.00
  • SCYX 0.10
  • MACD
  • SUNS 0.00
  • SCYX 0.01
  • Stochastic Oscillator
  • SUNS 0.00
  • SCYX 35.92

About SUNS Sunrise Realty Trust Inc. Common Stock

Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS and debt-like preferred equity securities across CRE asset classes and investment mix to include high quality multi-family, condominiums, retail, office, hospitality, industrial, mixed use and specialty-use real estate.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: